Cell viability in CaSki cervical cancer cells

Cell viability in CaSki cervical cancer cells is a phenotypic endpoint used to evaluate the effectiveness of potential therapeutic agents against cervical carcinoma. CaSki is a well-characterized human cell line derived from a metastatic cervical cancer site, notable for containing high copy numbers of Human Papillomavirus type 16 (HPV-16) and type 18 (HPV-18) (Source: ATCC, CRL-1550; PubMed: 2553590). Measuring cell viability involves quantifying the proportion of live cells in a population following treatment, often through metabolic indicators like the MTT, XTT, or CCK-8 assays (Source: NIH Assay Guidance Manual). This metric serves as a primary screen for anti-tumor activity, reflecting the cumulative effect of a drug on various biological processes such as the cell cycle, apoptosis, and metabolic health. While it is a critical parameter in drug discovery, it does not represent a single molecular target like a receptor or enzyme, but rather the overall physiological state of the cell line. Consequently, researchers use this metric to identify compounds that can successfully inhibit the growth of HPV-positive malignant cells (Source: PubMed: 10413408).

Other names

CaSki cell survivalCaSki cytotoxicity assayCaSki cell proliferationCaSki metabolic activity

Not applicable as this is a phenotypic measurement of cellular health rather than a specific molecular target.